TW202321250A - 治療性化合物 - Google Patents
治療性化合物 Download PDFInfo
- Publication number
- TW202321250A TW202321250A TW111129895A TW111129895A TW202321250A TW 202321250 A TW202321250 A TW 202321250A TW 111129895 A TW111129895 A TW 111129895A TW 111129895 A TW111129895 A TW 111129895A TW 202321250 A TW202321250 A TW 202321250A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- formula
- compound
- foregoing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231220P | 2021-08-09 | 2021-08-09 | |
| US202163231219P | 2021-08-09 | 2021-08-09 | |
| US63/231,219 | 2021-08-09 | ||
| US63/231,220 | 2021-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202321250A true TW202321250A (zh) | 2023-06-01 |
Family
ID=83149068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111129895A TW202321250A (zh) | 2021-08-09 | 2022-08-09 | 治療性化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11993599B2 (enExample) |
| EP (1) | EP4384517A1 (enExample) |
| JP (1) | JP2024533990A (enExample) |
| KR (1) | KR20240046498A (enExample) |
| AU (1) | AU2022328137A1 (enExample) |
| CA (1) | CA3225467A1 (enExample) |
| TW (1) | TW202321250A (enExample) |
| WO (1) | WO2023018648A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225467A1 (en) | 2021-08-09 | 2023-02-16 | Genentech, Inc. | Phenol derivatives for use in the modulation of brm |
| EP4540242A1 (en) * | 2022-06-16 | 2025-04-23 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| WO2024214019A1 (en) | 2023-04-12 | 2024-10-17 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2019207538A1 (en) | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
| EP3787747A4 (en) | 2018-04-30 | 2022-01-12 | Dana-Farber Cancer Institute, Inc. | POLYBROMO-1 (PBRM1) SMALL MOLECULE DEGRADATION PRODUCTS |
| EP3817822A4 (en) * | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020078933A1 (en) | 2018-10-16 | 2020-04-23 | Boehringer Ingelheim International Gmbh | Proteolysis targeting chimera (protacs) as degraders of smarca2 and/or smarca4 |
| FR3090393B1 (fr) | 2018-12-20 | 2021-04-23 | Ifp Energies Now | Procédé de traitement d’une charge alcool pour la production d’oléfines |
| WO2020172655A1 (en) | 2019-02-23 | 2020-08-27 | New York University | Photoswitchable protacs and synthesis and uses thereof |
| WO2020251971A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US20220324880A1 (en) * | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2020251969A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| BR112022004573A2 (pt) | 2019-09-12 | 2022-06-07 | Aurigene Discovery Tech Ltd | Método para identificar respondedores para degradadores de smarca2/4 |
| WO2021067606A1 (en) * | 2019-10-01 | 2021-04-08 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| EP4054724A4 (en) | 2019-10-28 | 2023-12-27 | C4 Therapeutics, Inc. | BIFUNCTIONAL CONNECTIONS |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| JP7706456B2 (ja) | 2020-01-10 | 2025-07-11 | アムジエン・インコーポレーテツド | Ｓｍａｒｃａ２－ｖｈｌ分解剤 |
| EP4132529A4 (en) | 2020-04-06 | 2024-05-01 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| JP2023529908A (ja) * | 2020-06-09 | 2023-07-12 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| TW202216215A (zh) * | 2020-07-21 | 2022-05-01 | 美商建南德克公司 | Ｂｒｍ降解之抗體結合化學誘導物及其方法 |
| WO2022109396A1 (en) | 2020-11-20 | 2022-05-27 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2022183056A1 (en) | 2021-02-26 | 2022-09-01 | Salk Institute For Biological Studies | Modulating regulatory t cell function in autoimmune disease and cancer |
| CA3225467A1 (en) | 2021-08-09 | 2023-02-16 | Genentech, Inc. | Phenol derivatives for use in the modulation of brm |
-
2022
- 2022-08-08 CA CA3225467A patent/CA3225467A1/en active Pending
- 2022-08-08 WO PCT/US2022/039696 patent/WO2023018648A1/en not_active Ceased
- 2022-08-08 KR KR1020247004828A patent/KR20240046498A/ko active Pending
- 2022-08-08 US US17/883,004 patent/US11993599B2/en active Active
- 2022-08-08 AU AU2022328137A patent/AU2022328137A1/en active Pending
- 2022-08-08 JP JP2024507995A patent/JP2024533990A/ja active Pending
- 2022-08-08 EP EP22761812.1A patent/EP4384517A1/en active Pending
- 2022-08-09 TW TW111129895A patent/TW202321250A/zh unknown
-
2024
- 2024-03-13 US US18/604,314 patent/US12428419B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4384517A1 (en) | 2024-06-19 |
| KR20240046498A (ko) | 2024-04-09 |
| US12428419B2 (en) | 2025-09-30 |
| WO2023018648A1 (en) | 2023-02-16 |
| AU2022328137A1 (en) | 2024-02-01 |
| US20240383897A1 (en) | 2024-11-21 |
| US20230112485A1 (en) | 2023-04-13 |
| US11993599B2 (en) | 2024-05-28 |
| JP2024533990A (ja) | 2024-09-18 |
| CA3225467A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11053215B2 (en) | Heterocyclic compounds useful as Pim kinase inhibitors | |
| WO2023066350A1 (zh) | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 | |
| AU2015261812B2 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors | |
| IL296918A (en) | Allosteric chromanone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation | |
| JP6437452B2 (ja) | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 | |
| US12428419B2 (en) | Therapeutic compounds | |
| EP4351558A1 (en) | Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes | |
| US20240246977A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use | |
| EA019785B1 (ru) | Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение | |
| EA017144B1 (ru) | N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором | |
| TW202214641A (zh) | Ｈｅｒ２突變抑制劑 | |
| JP2016528298A (ja) | Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 | |
| JP7511097B1 (ja) | Ｈｅｒ２変異阻害薬 | |
| CA3108676A1 (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
| PT2356123E (pt) | Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos | |
| KR20210061337A (ko) | 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도 | |
| TW202417458A (zh) | 調節her2的化合物及方法 | |
| KR20210100612A (ko) | 시클로알칸-1,3-디아민 유도체 | |
| KR20210083287A (ko) | 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체 | |
| CA3213823A1 (en) | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof | |
| CN117794933A (zh) | 用于调节brm的酚衍生物 | |
| HK40111551A (zh) | 用於调节brm的酚衍生物 | |
| US20250235456A1 (en) | Methods of use for aza-quinazoline compounds | |
| EA050708B1 (ru) | Деградация тирозинкиназы брутона (btk) посредством конъюгации ингибиторов btk с лигандом лигазы е3 и способы применения | |
| JP2024089651A (ja) | Ｈｅｒ２変異阻害薬 |